91 related articles for article (PubMed ID: 11686086)
1. Antithrombin and anti-Xa agents in the control of thrombogenesis.
Fareed J; Shaikh T; Hoppensteadt DA
Pharmazie; 2001 Oct; 56 Suppl 1():S12-21. PubMed ID: 11686086
[TBL] [Abstract][Full Text] [Related]
2. Factor Xa inhibitors: today and beyond.
Walenga JM; Jeske WP; Hoppensteadt D; Fareed J
Curr Opin Investig Drugs; 2003 Mar; 4(3):272-81. PubMed ID: 12735228
[TBL] [Abstract][Full Text] [Related]
3. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
4. Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.
Fevig JM; Cacciola J; Buriak J; Rossi KA; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2006 Jul; 16(14):3755-60. PubMed ID: 16682200
[TBL] [Abstract][Full Text] [Related]
5. Selective and dual action orally active inhibitors of thrombin and factor Xa.
Young RJ; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Hubbard JA; Kelly HA; Pateman AJ; Patikis A; Senger S; Shah GP; Toomey JR; Watson NS; Zhou P
Bioorg Med Chem Lett; 2007 May; 17(10):2927-30. PubMed ID: 17420122
[TBL] [Abstract][Full Text] [Related]
6. [New antithrombotic oligosaccharides].
Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
Ann Pharm Fr; 1999 May; 57(3):232-9. PubMed ID: 10427858
[TBL] [Abstract][Full Text] [Related]
7. [From heparin to synthetic antithrombotic oligosaccharides].
Petitou M
Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
[TBL] [Abstract][Full Text] [Related]
8. Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Furugohri T; Shiozaki Y; Muramatsu S; Honda Y; Matsumoto C; Isobe K; Sugiyama N
Eur J Pharmacol; 2005 May; 514(1):35-42. PubMed ID: 15878322
[TBL] [Abstract][Full Text] [Related]
9. Leech-derived thrombin inhibitors: from structures to mechanisms to clinical applications.
Corral-Rodríguez MA; Macedo-Ribeiro S; Pereira PJ; Fuentes-Prior P
J Med Chem; 2010 May; 53(10):3847-61. PubMed ID: 20155915
[No Abstract] [Full Text] [Related]
10. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).
Petitou M; Duchaussoy P; Jaurand G; Gourvenec F; Lederman I; Strassel JM; Bârzu T; Crépon B; Hérault JP; Lormeau JC; Bernat A; Herbert JM
J Med Chem; 1997 May; 40(11):1600-7. PubMed ID: 9171870
[TBL] [Abstract][Full Text] [Related]
11. [New thrombolytic agents. Thrombin and factor Xa inhibitors].
Heinzl S
Med Monatsschr Pharm; 2001 May; 24(5):142-6. PubMed ID: 11398649
[No Abstract] [Full Text] [Related]
12. Factor Xa is a superior target to factor IIa for antithrombotic therapies.
Büller HR
Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():37. PubMed ID: 14730477
[No Abstract] [Full Text] [Related]
13. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model.
Suleymanov OD; Szalony JA; Salyers AK; LaChance RM; Parlow JJ; South MS; Wood RS; Nicholson NS
J Pharmacol Exp Ther; 2003 Sep; 306(3):1115-21. PubMed ID: 12829728
[TBL] [Abstract][Full Text] [Related]
15. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro.
Jiang X; Crain EJ; Luettgen JM; Schumacher WA; Wong PC
Thromb Haemost; 2009 Apr; 101(4):780-2. PubMed ID: 19350128
[No Abstract] [Full Text] [Related]
16. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
17. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring.
Ueno H; Yokota K; Hoshi J; Yasue K; Hayashi M; Hase Y; Uchida I; Aisaka K; Katoh S; Cho H
J Med Chem; 2005 May; 48(10):3586-604. PubMed ID: 15887966
[TBL] [Abstract][Full Text] [Related]
19. Novel factor Xa inhibitors based on a benzoic acid scaffold and incorporating a neutral P1 ligand.
Nazaré M; Matter H; Klingler O; Al-Obeidi F; Schreuder H; Zoller G; Czech J; Lorenz M; Dudda A; Peyman A; Nestler HP; Urmann M; Bauer A; Laux V; Wehner V; Will DW
Bioorg Med Chem Lett; 2004 Jun; 14(11):2801-5. PubMed ID: 15125936
[TBL] [Abstract][Full Text] [Related]
20. Kinetic considerations on the physiologic control of thrombin and factor Xa.
Scully MF
Semin Thromb Hemost; 1992; 18(2):218-23. PubMed ID: 1631569
[No Abstract] [Full Text] [Related]
[Next] [New Search]
